The prevalence of BRCA1/2 mutations was enriched in our cohort as compared to the prevalence of BRCA1/2 mutations among all women with ovarian cancer (15 %) (US Preventive Services Task Force et al., 2019). This evidence concerns the gene BRCA1 and ovarian carcinoma.